Filing Flows › CareDx (CDNA) › Q3 2026
CareDx (CDNA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 29, 2026
CareDx (CDNA) reported revenue of $139M for the third quarter 2026 (Q3 2026), +39% from a year earlier and +6% from the quarter before. Operating margin was 5.8%, net earnings $19.3M (13.8% of revenue).
CareDx, Q3 2026: revenue $139M (+39% year over year), operating margin 5.8%, net earnings $19.3M, operating cash flow $12.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $139M | +6% | +39% |
| Operating profit | $8.1M | -93% | — |
| Net earnings | $19.3M | -83% | 12× |
| Operating cash flow | $12.7M | -58% | -66% |
| Free cash flow | $11.1M | -61% | -69% |
What changed
Revenue was $139.4M in Q3 2026, up 39% year over year and up 6% from the previous quarter. Testing services revenue was the largest line at 86% of revenue. Testing services revenue added $47.0M year over year (up 65%), 120% of the total change.
Operating profit was $8.1M, a 5.8% margin (up 6.1 points year over year). Total costs grew 31% against revenue growth of 39%. The fastest-growing cost line was General & admin (+34%). Net earnings were $19.3M, up 1052% year over year. The effective tax rate was -80.4%. Non-operating items added $2.6M, 24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $12.7M (down 66% year over year), 66% of net earnings. Non-cash charges added back $7.2M of depreciation and amortization and $9.7M of share-based compensation. Working capital and other items used $23.4M. Capital expenditures of $1.6M left free cash flow of $11.1M.
Questions
What was CareDx's revenue in the third quarter 2026?
CareDx (CDNA) reported revenue of $139M for the third quarter 2026 (Q3 2026), +39% from a year earlier and +6% from the quarter before.
Was CareDx profitable in the third quarter 2026?
Operating profit was $8.1M (5.8% of revenue) and net earnings $19.3M.
Source: CareDx 10-Q on SEC EDGAR.